[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586499":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":26,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":26,"eligibilityCriteria":39,"healthyVolunteers":40,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":26,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":26,"overallStatus":53,"whyStopped":26,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":26},{"fullName":5,"class":6},"Ahn-Gook Pharmaceuticals Co.,Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1: Coadministration of AG23041 and AG23042, Period 2: AG2304",[13,14],"Drug: AG2304","Drug: AG23041 and AG23042",{"label":16,"type":17,"description":18,"interventionNames":19},"Sequence B","ACTIVE_COMPARATOR","Period 1: AG2304, Period 2: Coadministration of AG23041 and AG23042",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","AG2304","AG2304, Single-dose Oral Administration",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"AG23041 and AG23042","AG23041\u002FAG23042, Single-dose Oral Administration",[9,16],{"type":32,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100586499","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ag2304-compared-to-coadministration-of-ag23041-and-ag23042-100586499",false,"NCT06916169","A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042","An Open-label, Randomized, Fasting, Single, Group 2, Stage 2, Cross-over Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* A healthy adults aged 19-65 years at the time of screening\n* Subjects who are deemed eligible based on the screening tests\n\nExclusion Criteria:\n\n* Subjects who have taken the investigational drug within 6 months prior to the first dose\n* Other exclusions have been applied",true,"ALL","19 Years","65 Years",{"count":45,"type":46},70,"ESTIMATED","INTERVENTIONAL",[49],"PHASE1","The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.",[52],"Pharmacokinetics","NOT_YET_RECRUITING","2025-04-02",{"date":56,"type":57},"2025-04-08","ACTUAL",{"date":59,"type":46},"2025-08",{"date":61,"type":46},"2025-09",{"name":5,"class":6}]